The decreased Apo-B level mediated by NPC1L1, PCSK9, ABCG5, ABCG8, and APOC3 gene targeted drugs were respectively associated with a higher IPF risk (OR = 3.46, 95% CI: 1.13 – 10.60, P = 0.030; OR = 1.39, 95% CI: 1.02 – 1.91, P = 0.038; OR = 1.85, 95% CI: 1.19 – 2.87, P = 0.006; OR = 1.88, 95% CI: 1.21 – 2.91, P = 0.005; OR = 2.25, 95% CI: 1.54 – 3.29, P = 2.82 × 10–5) (Fig. 4. This evidence concerns the gene APOC3 and idiopathic pulmonary fibrosis.